Published in Hepatitis Weekly, April 3rd, 2006
Recently, Boehringer Ingelheim and the external independent Data Safety Monitoring Board (DSMB) reviewed data from one of these ongoing clinical trials, study 1182.33, which is designed to evaluate the efficacy and safety of Aptivus /ritonavir in treatment-naive HIV-infected patients. Following a thorough review of the 48-week data...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.